December 15, 2020 -- GenScript Biotech has signed an agreement with InnoBation for cell line development and engineering and manufacturing services for InnoBation's good manufacturing practice plasmids and lentivirus products for chimeric antigen receptor (CAR) T-cell treatment products.
InnoBation is focused on the development of a bispecific CAR T therapy and several other CAR T products to treat hematological malignancies and tumors.
Under the agreement, GenScript will provide contract research organization services for developing engineered cell lines using CRISPR/Cas9 technology. GenScript ProBio, the contract development and manufacturing organization division of GenScript, will provide platform services for the development and manufacturing of plasmids and lentivirus products for preclinical and clinical trials.
Financial details of the agreement were not disclosed.
Copyright © 2020 scienceboard.net